Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $90,948 | 59 | 52.9% |
| Consulting Fee | $65,347 | 11 | 38.0% |
| Food and Beverage | $6,213 | 111 | 3.6% |
| Travel and Lodging | $4,812 | 17 | 2.8% |
| Honoraria | $4,510 | 2 | 2.6% |
| Education | $23.68 | 2 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $92,449 | 74 | $0 (2024) |
| Channel Medsystems, Inc. | $47,010 | 8 | $0 (2023) |
| Boston Scientific Corporation | $11,173 | 17 | $0 (2019) |
| Astellas Pharma US Inc | $6,441 | 14 | $0 (2024) |
| Meditrina | $5,732 | 4 | $0 (2024) |
| PFIZER INC. | $4,803 | 5 | $0 (2022) |
| Gynesonics, Inc. | $1,072 | 9 | $0 (2024) |
| Allen Medical Systems | $800.00 | 1 | $0 (2019) |
| ABBVIE INC. | $625.45 | 24 | $0 (2023) |
| Aspira Women's Health Inc | $459.50 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19,714 | 11 | Bayer Healthcare Pharmaceuticals Inc. ($19,250) |
| 2023 | $35,673 | 30 | Channel Medsystems, Inc. ($16,596) |
| 2022 | $41,674 | 24 | Channel Medsystems, Inc. ($30,415) |
| 2021 | $609.98 | 10 | Gynesonics, Inc. ($283.04) |
| 2020 | $19,858 | 48 | Bayer HealthCare Pharmaceuticals Inc. ($19,650) |
| 2019 | $39,225 | 24 | Bayer HealthCare Pharmaceuticals Inc. ($32,450) |
| 2018 | $14,481 | 43 | Bayer HealthCare Pharmaceuticals Inc. ($8,725) |
| 2017 | $619.99 | 12 | HOLOGIC INC ($225.85) |
All Payment Transactions
202 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | Gynesonics, Inc. | SONATA SONOGRAPHY-GUIDED TRANSCERVICAL FIBROID ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $120.39 | General |
| Category: SONATA TRANSCERVICAL FIBROID ABLATION SYSTEM | ||||||
| 11/18/2024 | Meditrina | — | Food and Beverage | Cash or cash equivalent | $43.63 | General |
| 10/31/2024 | Aspira Women's Health Inc | OVA1 (Device) | Food and Beverage | In-kind items and services | $14.03 | General |
| Category: OB/GYN | ||||||
| 09/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Essure (Device) | — | Cash or cash equivalent | $1,650.00 | Research |
| Study: A multi-centre, multi-national clinical study to evaluate the safety and effectiveness of the Essure (Model ESS505) device to prevent pregnancy in women who are seeking permanent contraception • Category: Womens Health | ||||||
| 08/27/2024 | Hologic Sales and Service, LLC | NOVASURE (Device) | Food and Beverage | In-kind items and services | $48.77 | General |
| Category: Surgical | ||||||
| 08/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Essure (Device) | — | Cash or cash equivalent | $3,300.00 | Research |
| Study: A multi-centre, multi-national clinical study to evaluate the safety and effectiveness of the Essure (Model ESS505) device to prevent pregnancy in women who are seeking permanent contraception • Category: Womens Health | ||||||
| 07/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Essure (Device) | — | Cash or cash equivalent | $4,950.00 | Research |
| Study: A multi-centre, multi-national clinical study to evaluate the safety and effectiveness of the Essure (Model ESS505) device to prevent pregnancy in women who are seeking permanent contraception • Category: Womens Health | ||||||
| 07/03/2024 | Bayer Healthcare Pharmaceuticals Inc. | Essure (Device) | — | Cash or cash equivalent | $4,950.00 | Research |
| Study: A multi-centre, multi-national clinical study to evaluate the safety and effectiveness of the Essure (Model ESS505) device to prevent pregnancy in women who are seeking permanent contraception • Category: Womens Health | ||||||
| 04/23/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $124.59 | General |
| Category: Biological | ||||||
| 04/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Essure (Device) | — | Cash or cash equivalent | $4,400.00 | Research |
| Study: A multi-centre, multi-national clinical study to evaluate the safety and effectiveness of the Essure (Model ESS505) device to prevent pregnancy in women who are seeking permanent contraception • Category: Womens Health | ||||||
| 02/27/2024 | Aspira Women's Health Inc | OVA1 (Device) | Food and Beverage | In-kind items and services | $112.35 | General |
| Category: OB/GYN | ||||||
| 11/30/2023 | Hologic Sales and Service, LLC | ACESSA PROVU SYSTEM (Device) | Food and Beverage | In-kind items and services | $25.60 | General |
| Category: Surgical | ||||||
| 11/07/2023 | Gynesonics, Inc. | SONATA SONOGRAPHY-GUIDED TRANSCERVICAL FIBROID ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $137.21 | General |
| Category: SONATA TRANSCERVICAL FIBROID ABLATION SYSTEM | ||||||
| 09/19/2023 | Bayer Healthcare Pharmaceuticals Inc. | Essure (Device) | — | Cash or cash equivalent | $1,400.00 | Research |
| Study: BAY1454033, pivotal • Category: Womens Health | ||||||
| 08/18/2023 | Bayer Healthcare Pharmaceuticals Inc. | Essure (Device) | — | Cash or cash equivalent | $2,800.00 | Research |
| Study: BAY1454033, pivotal • Category: Womens Health | ||||||
| 07/31/2023 | Bayer Healthcare Pharmaceuticals Inc. | Essure (Device) | — | Cash or cash equivalent | $4,900.00 | Research |
| Study: BAY1454033, pivotal • Category: Womens Health | ||||||
| 07/27/2023 | Bayer Healthcare Pharmaceuticals Inc. | Mirena (Drug), Kyleena | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: Womens Health | ||||||
| 07/14/2023 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: Biological | ||||||
| 07/11/2023 | Gynesonics, Inc. | SONATA SONOGRAPHY-GUIDED TRANSCERVICAL FIBROID ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $19.18 | General |
| Category: SONATA TRANSCERVICAL FIBROID ABLATION SYSTEM | ||||||
| 06/16/2023 | Astellas Pharma US Inc | Veozah (Drug) | Consulting Fee | Cash or cash equivalent | $4,597.00 | General |
| Category: Biological | ||||||
| 06/16/2023 | Bayer Healthcare Pharmaceuticals Inc. | Essure (Device) | — | Cash or cash equivalent | $3,150.00 | Research |
| Study: BAY1454033, pivotal • Category: Womens Health | ||||||
| 06/16/2023 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $300.98 | General |
| Category: Biological | ||||||
| 06/16/2023 | Astellas Pharma US Inc | Veozah (Drug) | Travel and Lodging | Cash or cash equivalent | $129.98 | General |
| Category: Biological | ||||||
| 06/15/2023 | Astellas Pharma US Inc | Veozah (Drug) | Travel and Lodging | Cash or cash equivalent | $517.80 | General |
| Category: Biological | ||||||
| 06/15/2023 | Astellas Pharma US Inc | Veozah (Drug) | Travel and Lodging | Cash or cash equivalent | $269.48 | General |
| Category: Biological | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| BAY1454033 pivotal | Bayer HealthCare Pharmaceuticals Inc. | $59,300 | 47 |
| A multi-centre, multi-national clinical study to evaluate the safety and effectiveness of the Essure (Model ESS505) device to prevent pregnancy in women who are seeking permanent contraception | Bayer Healthcare Pharmaceuticals Inc. | $19,250 | 5 |
| BAY1454033, pivotal | Bayer Healthcare Pharmaceuticals Inc. | $12,250 | 4 |
| Bay1002670 Endometriosis Dose finding EU & US JP CN | Bayer HealthCare Pharmaceuticals Inc. | $148.04 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 68 | 68 | $6,216 | $2,880 |
| 2022 | 2 | 66 | 66 | $5,835 | $3,284 |
| 2021 | 2 | 69 | 73 | $5,995 | $3,657 |
| 2020 | 2 | 56 | 60 | $4,675 | $2,345 |
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 35 | 35 | $4,025 | $1,656 | 41.1% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2023 | 33 | 33 | $2,191 | $1,224 | 55.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 28 | 28 | $3,220 | $1,813 | 56.3% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2022 | 38 | 38 | $2,615 | $1,471 | 56.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 29 | 33 | $3,795 | $2,111 | 55.6% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2021 | 40 | 40 | $2,200 | $1,546 | 70.3% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2020 | 40 | 40 | $2,375 | $1,579 | 66.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 16 | 20 | $2,300 | $766.38 | 33.3% |
About Dr. Gerard Reilly, M.D
Dr. Gerard Reilly, M.D is a Obstetrics & Gynecology healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1326041740.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gerard Reilly, M.D has received a total of $171,854 in payments from pharmaceutical and medical device companies, with $19,714 received in 2024. These payments were reported across 202 transactions from 26 companies. The most common payment nature is "" ($90,948).
As a Medicare-enrolled provider, Reilly has provided services to 259 Medicare beneficiaries, totaling 267 services with total Medicare billing of $12,165. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.
Practice Information
- Specialty Obstetrics & Gynecology
- Location Cincinnati, OH
- Active Since 05/31/2005
- Last Updated 03/06/2025
- Taxonomy Code 207V00000X
- Entity Type Individual
- NPI Number 1326041740
Products in Payments
- Non-Covered $59,448
- Essure (Device) $31,607
- Veozah (Drug) $6,362
- Aveta (Device) $5,600
- GENERAL UTERINE TISSUE REMOVAL (Device) $5,275
- MYFEMBREE (Drug) $4,968
- SYMPHION (Device) $4,408
- SONATA SONOGRAPHY-GUIDED TRANSCERVICAL FIBROID ABLATION SYSTEM (Device) $1,072
- THERAPIES (Device) $942.04
- Yellofins Stirrups with Lift Assist (Device) $800.00
- OVA1 (Device) $459.50
- GENERAL THERAPIES (Device) $447.17
- ACESSA PROVU SYSTEM (Device) $221.87
- Orilissa (Drug) $204.63
- ORILISSA (Drug) $158.72
- MYOSURE (Device) $124.17
- FLOSEAL (Biological) $116.33
- Lupron (Drug) $115.17
- LO LOESTRIN FE (Drug) $112.72
- GENERAL - UTERINE TISSUE REMOVAL (Device) $94.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Obstetrics & Gynecology Doctors in Cincinnati
Dr. David Schwartz, Md, MD
Obstetrics & Gynecology — Payments: $423,330
Amanda Jackson, Md, MD
Obstetrics & Gynecology — Payments: $116,912
Dr. Michael Karram, M.d, M.D
Obstetrics & Gynecology — Payments: $65,177
Sunbal Javaid, Md, MD
Obstetrics & Gynecology — Payments: $52,479
James Sosnowski, Md, MD
Obstetrics & Gynecology — Payments: $33,251
Dr. Gretchen Fermann, M.d, M.D
Obstetrics & Gynecology — Payments: $30,495